

Preliminary Programme

European Congress of
Clinical Microbiology
and Infectious Diseases

Barcelona, Spain
27–30 April 2024

ECCMID



34th

Disclaimer & Dates

Disclaimer

The following ECCMID 2024 scientific programme is preliminary only, and does not represent the entirety of the ECCMID invited programme. Speakers and chairpersons will be added to sessions as they are confirmed.

Integrated symposia from industry partners will also be published once confirmed in the website section dedicated to sponsors.

The ECCMID 2024 scientific programme is expected to be finalised in March of 2024.

Present your research and be part of ECCMID!

ECCMID has become one of the most comprehensive and influential congresses in the field of infection and an exciting networking place bringing together >16,000 colleagues from all over the world. Share and discuss your research with colleagues from around the world.

Abstract submission

Regular abstracts can be submitted from 16 October 2023 to 29 November 2023, 16:00 CET.

Late breaker abstracts submission will open in late January 2024.

Registration

Early Bird fee	until 14.02.2024
Regular fee	from 15.02.2024 to 13.03.2024
Late fee	from 14.03.2024

Preliminary Programme

Keynote Lectures

Keynote Lecture

Viral infections in stem cell transplantation: a lifetime journey

Per Ljungman (Stockholm, Sweden)



Per Ljungman is currently senior physician in the Dept. of Cellular Therapy and Allogeneic Stem Cell Transplantation and emeritus professor at Karolinska Institutet. He received his MD and PhD degrees from Karolinska Institutet and performed a post doctoral fellowship at the Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA. He is board qualified in internal medicine and hematology. His research interests have been virus infections in the severely immunocompromised host represented by patients undergoing allogeneic stem cell transplantation primarily CMV, other herpesviruses, and community acquired respiratory virus infections most recently SARS-CoV-2 currently chairing the EBMT COVID-19 Task Force. Another research area where Per Ljungman has been very active is in vaccination of stem cell transplant patients. He has performed several clinical trials as principal investigator both regarding antivirals and vaccines.

Keynote Lecture

Genomic surveillance for AMR: supporting public health interventions against typhoid and *Klebsiella pneumoniae*

Kathryn Holt (London, United Kingdom)



Kat is a computational biologist specialising in infectious disease genomics. She is Professor of Microbial Systems Genomics, and co-Director of the Antimicrobial Resistance (AMR) Centre, at London School of Hygiene and Tropical Medicine. Kat holds a BA/BSc, Master of Epidemiology, and PhD in Molecular Biology. Kat and her team are particularly interested in the evolution and spread of AMR, and vaccine design and deployment against AMR pathogens. Two organisms of particular focus are *Salmonella* Typhi (the agent of typhoid fever), and *Klebsiella pneumoniae* (a leading cause of neonatal sepsis and healthcare-associated infections globally). To support genomics-informed research and surveillance for these pathogens, Kathryn's team have developed organism-specific genomic typing tools (Kleborate and Kaptive for *Klebsiella*, GenoTyphi for Typhi), and cofounded international collaborative consortia (KlebNET, and the Global Typhoid Genomics Consortium).

Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM)

Keynote Scientific Interview

The syndemic of HIV and STIs

Jeanne Marrazzo (Bethesda, United States)



Dr. Marrazzo is the Director of the National Institute of Allergy and Infectious Diseases at the U.S. National Institutes of Health (NIH), where she oversees a \$6.3 billion budget that supports research to advance understanding, diagnosis, and treatment of infectious, immunologic, and allergic diseases. She was previously the C. Glenn Cobbs Endowed Chair and Director of Infectious Diseases at the University of Alabama at Birmingham Heersink School of Medicine. She is a Fellow of the American College of Physicians and the Infectious Diseases Society of America (IDSA), and was Treasurer of the IDSA from 2021-2023, having served on the board since 2018. Dr. Marrazzo researches the vaginal microbiome, sexually transmitted infections, and HIV pre-exposure prophylaxis. She has had leadership roles in the NIH HIV Prevention Trials Network and the Infectious Diseases Clinical Research Consortium. She has been a leading voice in communicating science during the COVID-19 pandemic.

Photo credit: NIH/Chia-Chi Charlie Chang

Co-organised with: Infectious Diseases Society of America (IDSA)

Preliminary Programme

Keynote Lectures

Keynote Lecture

The role of trained Innate Immunity in infections



Mihai Netea (Nijmegen, Netherlands)

Mihai Netea studied medicine in Cluj-Napoca, Romania. He completed his PhD at the Radboud University Nijmegen, The Netherlands, on stud Mihai Netea studied medicine in Cluj-Napoca, Romania. He completed his PhD at the Radboud University Nijmegen, The Netherlands, on studies investigating the cytokine network in sepsis. After working as a post-doc at the University of Colorado, he returned to Nijmegen where he finished his clinical training as an infectious diseases specialist, and where he currently heads the division of Experimental Medicine, Department of Internal Medicine, Nijmegen University Nijmegen Medical Center. He is mainly interested in understanding the memory traits of innate immunity (trained immunity), the factors influencing variability of human immune responses, and the immune dysregulation during bacterial and fungal infections. He is the recipient of the Spinoza Prize 2016 and an ERC Advanced grant in 2019, and since 2016 he is a member of the Netherlands Royal Academy of Sciences (KNAW).

Co-organised with: UEMS Section of Infectious Diseases

Keynote Lecture

Innovations in diagnosis, treatment and prevention of malaria



Sodiomon B. Sirima (Ouagadougou, Burkina Faso)

Sodiomon Bienvenu Sirima, is an expert on clinical trials and is one of the African pioneer in ICH-GCP implemented Malaria vaccine trials. He is holding a Doctorate in Medicine and Surgery (MD), a Bachelor Socio-anthropology (BA) and a PhD in epidemiology. Since 2016 Dr Sirima is the scientific Director of the Groupe de Recherche Action en Santé, Ouagadougou, in Burkina Faso, an independent, local, non-governmental research center founded in 2008 an actively partnering with the Ministry of Health and Ministry of Science and Technology of Burkina Faso. During these last 25 years Sodiomon B. Sirima has led more than thirty epidemiological and community-based studies and more than fifteen ICH-GCP compliant clinical trials. These studies have led to a significant policy changes in malaria control strategies. At Burkina Faso level, he is one of the key opinion leaders in the malaria field. Current research projects include Typhoid, Schistosomiasis, shigella and malaria vaccines and, drug clinical trials.

Keynote Lecture

New frontiers in microbiome and human health

Nicola Segata (Trento, Italy)



Nicola Segata, Ph.D., is Professor and Principal Investigator at the CIBIO Department of the University of Trento (Italy) and Principal Investigator at the European Institute of Oncology in Milan (Italy). He earned his Ph.D. in Computer Science at University of Trento in 2009 and he then moved to Harvard School of Public Health for his post-doctoral training where he started studying the human microbiome with computational metagenomics approaches in the Laboratory of Prof. Curtis Huttenhower. He came back to University of Trento (Department CIBIO) where he started his laboratory in 2013 which employs experimental meta'omic tools and novel computational approaches to study the diversity of the human microbiome across conditions and populations and its role in human diseases. His work is supported by the European Research Council and by several other European agencies. The projects in his laboratory bring together computer scientists, microbiologists, statisticians, and clinicians and focus on profiling microbiomes with strain-level resolution and on meta-analysing very large sets of metagenomes with novel computational tools.

Keynote Lecture

Redefining sepsis: past and future

Mervyn Singer (London, United Kingdom)



Professor of Intensive Care Medicine at University College London, UK. Published mainly on sepsis and multi-organ failure, infection, shock, monitoring. Developed various monitoring and support devices and has two 'home-made' drugs and two devices in current development. Co-chaired Sepsis-3 Definitions International Task Force and past-Chair, International Sepsis Forum. Sepsis Topic Advisor to NICE. Written various textbooks e.g. Oxford Handbook of Critical Care. Has run Medical Emergencies Courses for >25 years. Emeritus NIHR Senior Investigator. Loves being iconoclastic and gently provocative.

Keynote Lecture

Emergence of group A streptococcal diseases: from Strep throat to invasive infections

Shiranee Sriskandan (London, United Kingdom)



Shiranee Sriskandan is Professor of Infectious Diseases at Imperial College London and a Clinical Infectious Diseases consultant at Hammersmith and St Mary's Hospitals. She leads the Gram-Positive Pathogenesis research group within the Department of Infectious Disease, and is clinical director of Imperial's new Centre for Bacteriology Resistance Biology. Her group works on the mechanisms that allow *Streptococcus pyogenes* to cause extreme clinical phenotypes in individuals and populations. The group's work ranges from pathogen virulence to host immune response and vaccines, and relies heavily on collaboration with colleagues in the UK and abroad.

Keynote Scientific Interview

A journey from microbiology to infection prevention and control in the era of AMR

Margreet Vos (Rotterdam, Netherlands)



Prof Dr Margreet C. Vos is a Clinical Microbiologist and since 2012, she is a professor of Healthcare related Infections at the ErasmusMC, Rotterdam, the Netherlands. Her main interests are infection prevention, in particular MSSA/MRSA, the Search and Destroy strategy, hand hygiene, outbreaks, transmission, innate environment, hospital environment and hospital design and endoscope related contamination and infections. She initiated and chaired for many years a national working group (HIP) as part of the Dutch Society of Medical Microbiology (NVMM) and initiated, developed and chaired the committee on infection control national guideline on the organization and quality of hospital infection prevention and developed audits for quality of hospital infection prevention. She was the project-leader of an international (UK FR NL) JPI MACOTRA consortium on (un)success of MRSA clones. She is the scientific officer of ESGNI and chair of the MRSA-ISAC working group.

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee

Preliminary Programme

2-hour Symposia

2-hour Symposium

Elimination of viral hepatitis: a puzzle still to be solved

Viral hepatitis elimination in 2024: have we moved forward?

Erika Duffell (Stockholm, Sweden)

Use of simplified approaches for screening and diagnosis of HCV, HBV and HDV infections

Simona Ruta (Bucharest, Romania)

The best we can do with the treatments we have: is it enough to eliminate HCV, HBV, HDV?

Adriana Vince (Zagreb, Croatia)

Hepatitis E in vulnerable populations

Zeinab Nabil (Cairo, Egypt)

Co-organised with: Croatian Society for Infectious Diseases of the Croatian Medical Association, ESCMID Study Group for Viral Hepatitis (ESGVH), Società Italiana di Malattie Infettive e Tropicali (SIMIT), Slovenian Society of Infectious Diseases, GEHEP-SEIMC (Study Group of Viral Hepatitis of the Spanish Society of Infectious Diseases and Clinical Microbiology)

2-hour Symposium

Preventing HIV: what more do we need?

Risk and benefits of breastfeeding in HIV-infected women receiving antiretroviral therapy

Angela Colbers (Nijmegen, Netherlands)

Novel and enhanced HIV-1 prevention strategies using broadly neutralising antibodies

Phillipp Schommers (Cologne, Germany)

Use of long-acting cART injectables for prevention of HIV infection

TBA

Gender inequalities in HIV prevention

TBA

Co-organised with: ESCMID International Affairs, Pan-American Association Infectious Diseases (API)

2-hour Symposium

A new kid on the block: the promises and challenges of molecular wastewater surveillance

Wastewater surveillance for public health: opportunities and pitfalls

Steen Ethelberg (Copenhagen, Denmark)

Epidemiological surveillance using waste water

Nicholas Grassly (London, United Kingdom)

Wastewater surveillance: ethical and legal aspects

Michelle M. Mello (Stanford, United States)

Wastewater surveillance in Africa: perspective for LMICs

Tafadzwa Dzinamarira (Lusaka, Zambia)

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Study Group for Public Health Microbiology (ESGPHM)

2-hour Symposium

Measles and polio eradication: where do we stand?

Current epidemiology of measles

Patrick O'Connor (Geneva, Switzerland)

Global measles eradication: how and when?

Hanna Nohynek (Helsinki, Finland)

Why is polio still a concern?

Thea Kølsen Fischer (Copenhagen, Denmark)

Vaccine-derived poliovirus outbreaks - new vaccine and enhanced surveillance

Cara Burns (Atlanta, United States)

Co-organised with: ESCMID Vaccine Study Group (EVASG)

2-hour Symposium

Endocarditis – new guidelines, approaches, and challenges

The 2023 ESC endocarditis guidelines – what's different?

TBA

Endocarditis in low- and middle-income countries

TBA

The battle against IE in the elderly: challenges and treatment options

*Martha Kestler Hernandez
(Madrid, Spain)*

Dental procedures and antibiotic prevention of infective endocarditis: what's new

Bruno Hoen (Paris, France)

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), Sociedad Española de Infecciones Cardiovasculares (SEICAV)

2-hour Symposium

New diagnostic and treatment interventions for tuberculosis based on the immune response

New perspectives on molecular endotyping that can improve patient stratification and guide clinical management

Andrew Di Nardo (Houston, United States)

Discovery of immune-enhancing therapies that prevent development of drug-resistant tuberculosis

Susanna Brighenti (Stockholm, Sweden)

Biomarkers for tuberculosis infection: from the host to the pathogen

Delia Goletti (Rome, Italy)

Targeting the innate immune response to improve outcomes in TB

*Jon S. Friedland
(London, United Kingdom)*

2-hour Symposium

Sepsis 2024: embracing transformative medicine in the daily practice

ISF awardee and ESGBIES Young Investigator

TBA

Precision medicine in sepsis: the time is now!

*Chaz Langelier
(San Francisco, United States)*

Evaluation of long-term sepsis sequelae

*Carolyn Fleischmann-Struzek
(Jena, Germany)*

Sepsis: year in review

*Joost Wiersinga
(Amsterdam, Netherlands)*

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), European Sepsis Alliance (ESA), International Sepsis Forum (ISF)

2-hour Symposium

Streptococcal infection: from invasive infection to post-infectious sequelae

Group A *Streptococcus*: burden of disease

Pierre Smeesters (Brussels, Belgium)

Streptococcus dysgalactiae subsp. *equisimilis*: an emerging cause of invasive infections

Oddvar Oppegaard (Bønes, Norway)

Invasive group A and B streptococcal infections in women and children

Anna Seale (London, United Kingdom)

Post-streptococcal sequelae: acute rheumatic fever and rheumatic heart disease

Liesl Zühlke (Cape Town, South Africa)

Preliminary Programme

2-hour Symposia

2-hour Symposium

Staphylococcus aureus bacteraemia: emerging guidelines and updates

Defining at-risk populations and treatment duration
Achim Kaasch (Magdeburg, Germany)

Diagnostic evaluation of SAB
Catherine Liu (Seattle, United States)

The use of adjuvant treatments in SAB
Anna Goodman (London, United Kingdom)

Management of MRSA
Mical Paul (Haifa, Israel)

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

2-hour Symposium

Plasticity of bacterial genomes: the wonders of horizontal gene transfer

Mobile genetic elements in bacteria: not only plasmids and transposons
Sally Partridge (Westmead, Australia)

Horizontal gene transfer and its role in antibiotic resistance spread
Monika Dolejska (Brno, Czech Republic)

Plasmidome-microbiome interactions
TBA

Challenges of tracing mobile genetic elements with whole genome sequencing
Henrik Hasman (Copenhagen, Denmark)

2-hour Symposium

Introduction of newer antibiotics in LMICs

Access to reserve antibiotics in LMICs
Jennifer Cohn (Geneva, Switzerland)

Newer antibiotics in the absence of diagnostic capacity: how to balance access and stewardship?
Céline Pulcini (Nancy, France)

Equitable distribution of antibiotics in LMICs
Mirfin Mpundu (Lusaku, Zambia)

Developing a national stewardship programme in South Africa
Marc Mendelson (Cape Town, South Africa)

Co-organised with: Global Antibiotic Research and Development Partnership (GARDP)

2-hour Symposium

Research agenda in One Health

One Health priority research agenda for AMR
Haileyesus Getahun (Geneva, Switzerland)

Translating research priorities into action for human health
Adrian John Brink (Cape Town, South Africa)

Estimating the economic burden and return on investment of AMR in environment
Chantal Morel (Bern, Switzerland)

Innovations in antibacterial development: WHO research and development pipeline
Valeria Gigante (Geneva, Switzerland)

Co-organised with: World Health Organisation (WHO)

2-hour Symposium

Providing access to laboratory diagnosis and surveillance in remote settings - problems and solutions

The value of global access to diagnostics
Yenew Kebede Tebeje (Addis Abbaba, Ethiopia)

The Mini-Lab: accessible clinical bacteriology at the district level
Alessandra Natale (Paris, France)

Rapidly deployable medical mobile lab for epidemic control
TBA

The Suitcase Lab: real-time, portable genome sequencing for outbreak surveillance
Sophie Durauffour (Hamburg, Germany)

Co-organised with: ESCMID Study Group for Public Health Microbiology (ESGPHM), ESCMID Study Group for Veterinary Microbiology (ESGVM)

2-hour Symposium

Moving phage therapy forward: from susceptibility testing to regulatory frameworks

Clinical phage microbiology: what does it mean?

Ronen Hazan (Jerusalem, Israel)

Standardising bacteriophage susceptibility testing: a long and winding road?

Maria del Mar Tomas (A Coruña, Spain)

Key variables in clinical research to assess efficacy of phage therapy

Shawna McCallin (Zurich, Switzerland)

Bacteriophages: it's a medicine, but not as we know it

Jean-Paul Pirnay (Brussels, Belgium)

Co-organised with: ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

2-hour Symposium

Beyond the label: treatment optimisation in special patient groups

Tiny patients, big decisions: navigating the challenges and opportunities of personalised antibiotic therapy in children

Tuuli Metsvaht (Tartu, Estonia)

Treating obese patients: emerging solutions

Amit Pai (Ann Arbor, United States)

Age ain't just a number: deciphering the altered PK/PD of antibiotics in older patients

Pieter De Cock (Gent, Belgium)

Administration of antibiotics to elderly – can we make it more elegantly?

Claire Roubaud-Baudron

(Bordeaux, France)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Infections in the Elderly (ESGIE)

2-hour Symposium

New strategies to treat infectious diseases

Innovative genetic engineering strategies to achieve antibacterial activity

Sarah Bigot (Lyon, France)

Natural antimicrobial peptides and their synthetic derivatives as an alternative to conventional antibiotics

Cagla Bozkurt Güzel (Istanbul, Turkey)

Monoclonal antibodies to treat infections

Bettina Fries (New York, United States)

How to improve sequential antibiotic therapy using evolutionary principles

Hinrich Schulenburg (Kiel, Germany)

Co-organised with: Deutsche Gesellschaft für Hygiene und Mikrobiologie, ESCMID Scientific Affairs Subcommittee

2-hour Symposium

Antimicrobial stewardship accreditation programmes around the world

Antimicrobial stewardship accreditation in Africa

Isabelle Mweenda

(Aberdeen, United Kingdom)

Antimicrobial stewardship accreditation in India

Anup Warriar (Kochi, India)

Antimicrobial stewardship accreditation in Australia

Karin Thursky (Karlton, Australia)

Antimicrobial stewardship accreditation in Spain

Antonio Lopez (Madrid, Spain)

Co-organised with: British Society for Antimicrobial Chemotherapy (BSAC)

Preliminary Programme

2-hour Symposia

2-hour Symposium

Fungal infections from a One Health perspective

Lesson learned from the animal kingdom
TBA

***Candida auris*: current epidemiology and battle plan**
Vincenzo Di Pilato (Genoa, Italy)

***Fusarium* outbreaks – expect the unexpected**
Fernanda Gonzalez (Mexico City, Mexico)

Fungal outbreaks on the horizon of climate change
Dee Carter (Sydney, Australia)

Co-organised with: ESCMID Fungal Infection Study Group (EFISG)

2-hour Symposium

Controversies and challenges in antifungal therapy

Reassessment of antifungal combination therapies: misuse versus rational indications
Monica Slavin (Melbourne, Australia)

Therapeutic drug monitoring: current indications and practical implementation of individualised dosing
Russel Lewis (Treviso, Italy)

Individualised dosing in the ICU: weight, third space, albumin, replacement therapies and other conundrums
Roger Brüggemann (Nijmegen, Netherlands)

New antifungal agents: latest developments and future perspectives
Martin Hoenigl (Graz, Austria)

Co-organised with: ESCMID Fungal Infection Study Group (EFISG), ESCMID Study Group for Infections in Compromised Hosts (ESGICH), Society of Infectious Diseases Pharmacists (SIDP)

2-hour Symposium

Climate change and the spectrum of infectious consequences

Ancient viruses revived from permafrost
Jean-Michel Claverie (Marseille, France)

Monitoring the effects of climate change on the distribution of infectious diseases
Rachel Lowe (Barcelona, Spain)

Climate change and AMR: challenges in a moving world
Sabiha Essack (Durban, South Africa)

Climate change and cholera
TBA

Co-organised with: Deutsche Gesellschaft für Infektiologie, ESCMID Professional Affairs Subcommittee, ESCMID Study Group for Infections in Travellers and Migrants (ESGTM), Trainee Association of ESCMID (TAE) Steering Committee

2-hour Symposium

Bacterial pathogens across One Health: a genomic view

Pathogenesis of human leptospirosis
TBA

Dissemination of *Burkholderia pseudomallei* in endemic and non-endemic settings
Bart Currie (Casuarina, Australia)

The genomic epidemiology of *Brucella melitensis* in humans and animal husbandries
Jacob Moran-Gilad (Beer Sheva, Israel)

Invasiveness and resistance of *Salmonella* in low resource countries
Sandra van Puyvelde (Wilrijk, Belgium)

2-hour Symposium

New approaches for malaria screening, management and prevention

Screening for imported malaria: who, how and why?

Anna Färnert (Stockholm, Sweden)

Management of malaria cases in the era of drug resistance

Phillippe Guerin (Oxford, United Kingdom)

Best practices for prevention of malaria transmission during transfusion and transplantations

Francesca Norman (Madrid, Spain)

Malaria prophylaxis – new recommendations and alternative dose schedule

Eli Schwartz (Ramat Gan, Israel)

Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGITM), ESCMID Professional Affairs Subcommittee, ESCMID Study Group for Clinical Parasitology (ESGCP), ESCMID Study Group for Infections in Compromised Hosts (ESGICH)

2-hour Symposium

Design does matter: Prevention through creating a microbe-safe hospital

The microbe-safe hospital: the role of design to optimise safety

TBA

Architectural design strategies for infection prevention and control in healthcare facilities: prepare for the future

TBA

Water and surfaces: where is the risk and how to prevent it

Hilary Humphreys (Dublin, Ireland)

Optimising healthcare ventilation

Catherine Noakes

(Leeds, United Kingdom)

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI)

2-hour Symposium

The microbiome and gut-brain axis in neurological diseases

The role of the gut microbiome in Alzheimer's disease

Giovanni Frisoni (Geneva, Switzerland)

The role of the gut microbiome in Parkinson's disease

Fiorella Contarino (Leiden, Netherlands)

The role of the gut microbiome in multiple sclerosis: potential for treatment?

Anne-Katrin Pröbstel (Basel, Switzerland)

The role of the gut microbiome in cerebrovascular disease

Bastiaan Haak (Amsterdam, Netherlands)

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI), ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

2-hour Symposium

Covert pathogenesis: unexpected impact of co-occurring organisms during polymicrobial infection

Cooperation and competition in the human nasal microbiota

Silvio Brugger (Zurich, Switzerland)

Co-ascending vaginal microbes during in utero infection

Katy Patras (Houston, United States)

Polymicrobial interactions in UTI

Marjon de Vos (Groningen, Netherlands)

Fungal-bacterial interactions in infections

Ilse Jacobsen (Jena, Germany)

2-hour Symposium

Translating fundamental science for treating biofilm infections

People are not petri plates: why antibiotics fail in biofilm infection treatment

Thomas Bjarnsholt

(Copenhagen, Denmark)

Microengineered models to study biofilm-associated urinary tract infections

John McKinney (Lausanne, Switzerland)

Antibiofilm peptides: overcoming biofilm-related treatment failure

Robert E.W. Hancock (Vancouver, Canada)

Nano-approaches to target biofilm infections

Rikke Louise Meyer (Aarhus, Denmark)

Preliminary Programme

2-hour Symposia | 1-hour Symposia

2-hour Symposium

Treatment strategies for transplant-associated infections

Adenovirus in stem-cell transplant recipients

Thomas Lion (Vienna, Austria)

CMV infection in the transplant setting

Atul Humar (Toronto, Canada)

BK virus in renal transplant - clinical management and development

Gabriel Westman (Uppsala, Sweden)

Burden and management of multidrug-resistant infections in SOT recipients

Maddalena Giannella (Bologna, Italy)

2-hour Symposium

The future of infection treatment and prevention in the immunocompromised

Biologicals and infection: a heterogeneous risk profile

Isabel Ruiz-Camps (Barcelona, Spain)

Cellular therapies for immunocompromised difficult-to-treat infections

Nina Khanna (Basel, Switzerland)

CAR-T complications: what does an ID specialist need to know?

Carlota Gudiol (Barcelona, Spain)

Xenotransplantation suddenly a reality: and xeno-zoonoses?

Kapil K. Saharia (Baltimore, United States)

Co-organised with: International Immunocompromised Host Society (ICHS)

2-hour Symposium

Making teaching work: from classical lectures to eLearning and beyond

Effective and engaging teaching: is eLearning the solution?

Jo Hart (Manchester, United Kingdom)

Bedside/benchside teaching and simulation: just entertaining or improving the outcomes?

Nathan Pfeiffer-Smadja (Paris, France)

Serious games design: tackling challenges and measuring educational impact

Nienke Beerlage-de Jong (Enschede, Netherlands)

How to produce impactful educational content on social media

Erin Bonura (Portland, United States)

Co-organised with: ESCMID Education Subcommittee, International Federation of Medical Students Associations (IFMSA)

2-hour Symposium

Risk communication: lessons learnt and best practices for the next pandemic

TBA

Kai Kupferschmidt (Berlin, Germany)

Scientific communication to the public during medical emergency

Siouxie Wiles (Auckland, New Zealand)

Communicating public health policy during medical emergency

Benjamin Djoudalbaye (Addis Ababa, Ethiopia)

TBA

Helen Branswell (New York, United States)

1-hour Symposium

Prevention of transfusion-associated infections

The challenge of occult HBV infected donors

*William Irving
(Nottingham, United Kingdom)*

Preventing transfusion-associated malaria in Europe

Sophie Le Cam (Paris, France)

Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), European Society for Clinical Virology (ESCV)

1-hour Symposium

Seasonal influenza, COVID-19 and RSV: where do we go?

Epidemiology and surveillance

Colin Russell (Amsterdam, Netherlands)

Laboratory-based and point-of-care diagnosis

Sylvie van der Werf (Paris, France)

Co-organised with: European Scientific Working group on Influenza (ESWI)

1-hour Symposium

Long COVID: from mechanism of injury to treatment

Mechanisms of post-COVID syndrome and therapeutic strategies

*Carmen Scheibenbogen
(Berlin, Germany)*

Update on recent developments in treatment of Long COVID

TBA

Co-organised with: European Medicines Agency (EMA), Collaborative on Fatigue Following Infection (COFFI)

1-hour Symposium

Changing epidemiology of West Nile Virus infections in Europe

West Nile virus surveillance in humans
Flavia Riccardo (Rome, Italy)

West Nile Virus infections: from animals to humans

Norbert Nowotny (Vienna, Austria)

Co-organised with: Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V.

1-hour Symposium

Human papillomavirus: should we immunise more than teens?

Current impact of the HPV vaccine according to vaccine coverage
Suzanne Garland (Parkville, Australia)

Adults above 25, and those who already experienced an HPV-associated disease: should we extend the target of vaccination?

Matthias Jentschke (Hannover, Germany)

Co-organised with: ESCMID Vaccine Study Group (EVASG)

1-hour Symposium

Chemotherapy and other options for drug-resistant tuberculosis

What are the chemotherapy options for drug-resistant TB?

Young Ae Kang (Seoul, Republic of Korea)

Search and destroy of latent TB: the best option for drug-resistant TB?

Raquel Duarte (Porto, Portugal)

Co-organised with: Korean Society of Clinical Microbiology (KSCM)

1-hour Symposium

New treatments for CNS infections

Dexamethasone in herpes encephalitis: are all votes in?

Tom Solomon (Liverpool, United Kingdom)

Progressive multifocal leukoencephalopathy treated by immune checkpoint inhibitors

*Guillaume Martin-Blondel
(Toulouse, France)*

Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

Preliminary Programme

1-hour Symposia

1-hour Symposium

Anaerobic bloodstream infections - diagnostic and treatment strategies

Diagnostic methods and resistance detection in anaerobic BSI
Ulrik S. Justesen (Odense, Denmark)

Clinical relevance and treatment strategies of anaerobic BSI
Roberta Maria Antonello (Florence, Italy)

Co-organised with: ESCMID Study Group for Anaerobic Infections (ESGAI)

1-hour Symposium

Convergent hypervirulence and multi-drug resistance in *Klebsiella pneumoniae*: the worst nightmare

Risk factors and clinical impact of hypervirulent multidrug-resistant *Klebsiella pneumoniae*
Şiran Keske (Istanbul, Turkey)

When to suspect hypervirulent *Klebsiella pneumoniae*: the role of laboratory diagnostics
Andrea Endimiani (Bern, Switzerland)

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

1-hour Symposium

Using evolutionary principles to fight antimicrobial resistance

Tackling tolerance to avoid antibiotic resistance development
Nathalie Questembert-Balaban (Jerusalem, Israel)

Evolved collateral susceptibility as a focus to optimise antibiotic therapy
Hinrich Schulenburg (Kiel, Germany)

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

1-hour Symposium

Carbapenems for treating multidrug-resistant Gram-negative infections: pro/con debate

Pro: carbapenems for patients with resistant micro-organisms
Pranita Tamma (Baltimore, United States)

Con: preserving carbapenems by using alternative antibiotics
Heiman Wertheim (Nijmegen, Netherlands)

Co-organised with: Dutch Committee on Antimicrobial Policy (SWAB), Society of Infectious Diseases Pharmacists (SIDP)

1-hour Symposium

Bacteraemia and antimicrobial resistance surveillance among vulnerable children

Carriage of antimicrobial resistance amongst hospitalised children in Africa
Sam Kariuki (Nairobi, Kenya)

Neonatal bacteraemia and antimicrobial resistance surveillance
Phoebe Williams (Sydney, Australia)

1-hour Symposium

Antimicrobial resistance among displaced populations

Challenges of antimicrobial stewardship in countries with expanding displaced populations in the Middle East
Souha S. Kanj (Beirut, Lebanon)

Ukraine war and antimicrobial resistance challenges
Sergii Antoniuk (Kiev, Ukraine)

Co-organised with: ESCMID International Affairs (EIAS)

1-hour Symposium

Single vs. separate venipunctures to draw the same blood volume for diagnosing bacteraemia: pros and cons

Single venipuncture
Brigitte Lamy (Nice, France)

Separate venipunctures
Michael L. Wilson (Denver, United States)

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES)

1-hour Symposium

Diagnostic stewardship: moulding clinician behaviour

Minding the moulds, advancing diagnostic stewardship in clinical practice
Cornelia Lass-Flörl (Innsbruck, Austria)

Empowering junior doctors with diagnostic stewardship principles
Johnny Zakhour (Detroit, United States)

Co-organised with: International Society of Antimicrobial Chemotherapy (ISAC)

1-hour Symposium

Don't forget the PETs in infection diagnosis and follow up

PET in Gram-positive bloodstream infection
Nesrin Ghanem-Zoubi (Haifa, Israel)

The use of PET in vascular graft infection
Barbara Hasse (Zurich, Switzerland)

Co-organised with: ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

1-hour Symposium

Decoding plasmids in diagnostics and infection control

Bacterial plasmid typing: state of the art
Alessandra Carattoli (Rome, Italy)

Making sense of plasmid-borne transmission of AMR
Teresa M. Coque (Madrid, Spain)

Co-organised with: ESCMID Emerging Infections Task Force (EITaF) chair, ESCMID Study Group for Lyme Borreliosis (ESGBOR)

1-hour Symposium

Emerging pathogens from the forensic perspective

Emerging and common human cardiotropic viruses as causes of sudden cardiac death
Laurent Andreoletti (Reims, France)

Moulds in the home environment: from allergies to sudden deaths in young children
Jean-Pierre Gangneux (Rennes, France)

Co-organised with: ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), European Network of Forensic Sciences Institutions (ENFSI)

1-hour Symposium

Top papers in antimicrobial pharmacology

The pharmacologist's selection
Erwin Dreesen (Leuven, Belgium)

The pharmacometrician's selection
Brenda de Winter (Rotterdam, Netherlands)

1-hour Symposium

Use of AI in antibiotic discovery and treatment adaptation

Antibiotic discovery with machine learning
Jonathan Stokes (Hamilton, Canada)

A machine learning approach coupled with population PK for optimisation of anti-infectious treatments
Jean Baptiste Woillard (Limoges, France)

1-hour Symposium

Behavioural insights and community engagement to influence appropriate antibiotic use

Using the WHO Tailoring Antimicrobial Resistance Programmes (TAP)
Ketevan Kandelaki (Copenhagen, Denmark)

Responsive dialogue toolkit for community engagement on AMR
Renier Coetzee (Cape Town, South Africa)

1-hour Symposium

Detection and control of rare fungal outbreaks

Rare yeast outbreaks and prevention strategies
Silke Schelenz (London, United Kingdom)

Rare mould outbreaks and control strategies in healthcare and community settings
Tom Chiller (Atlanta, United States)

Preliminary Programme

1-hour Symposia

1-hour Symposium

***Pneumocystis jirovecii* pneumonia: diagnostic updates**

Pneumocystis jirovecii pneumonia in the ICU patient

Daniele Giacobbe (Genoa, Italy)

Strengths and limitations of *Pneumocystis jirovecii* pneumonia molecular diagnostics

Riina Richardson

(Manchester, United Kingdom)

Co-organised with: ESCMID Fungal Infection Study Group (EFISG)

1-hour Symposium

Tropical diseases: management dilemmas and newer concepts

Management dilemmas in cysticercosis

Hector H. Garcia (Lima, Peru)

Dengue - newer antivirals and host modulating therapies

Neelika Malavige (Colombo, Sri Lanka)

1-hour Symposium

NTDs with skin manifestations: Diagnostic and treatment challenges

Cutaneous leishmaniasis

TBA

NTMs: Buruli ulcer and Hansen's disease

Pedro Legua (Lima, Peru)

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP), ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

1-hour Symposium

Top papers in tropical medicine and clinical parasitology

Top papers in tropical medicine

Martin Montes (Lima, Peru)

Top papers in clinical parasitology

Priscilla Rupali (Vellore, India)

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

1-hour Symposium

Health and hygiene in maternal and neonatal units across the world

Infection prevention and control in maternity and neonatal units in low-and middle-income countries

TBA

Infection prevention in the neonatal intensive care unit in high income countries – the neonatologists perspective

Angelika Berger (Vienna, Austria)

Co-organised with: European Society of Paediatric Infectious Diseases (ESPID)

1-hour Symposium

Healthcare-associated infections: data for action and prevention standards to improve patient safety

Infection prevention and control standards and safe workflows for patients with special medical conditions

Sarah Tschudin-Sutter (Basel, Switzerland)

Healthcare-associated infections in Europe in the aftermath of the COVID-19 pandemic: results of the 3rd ECDC PPS

Carl Suetens (Stockholm, Sweden)

1-hour Symposium

Screening for the control of multidrug-resistant organisms in hospitals: adapting strategies to cross-border care needs

Epidemiology of cross-border transmission of multidrug-resistant organisms to hospitals in Europe

Mikael Kajova (Helsinki, Finland)

MDRO admission screening for cross-border hospital care

TBA

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), ESCMID Study Group for Public Health Microbiology (ESGPHM)

1-hour Symposium

Automated surveillance of bloodstream infections

Multinational electronic surveillance systems for bloodstream infections in EU/EEA
Diamantis Plachouras (Solna, Sweden)

Automated surveillance of healthcare-associated infections
Maaïke van Mourik (Zeist, Netherlands)

Co-organised with: European Centre for Disease Prevention and Control (ECDC)

1-hour Symposium

Antibiotic hetero-resistance: does it matter?

Single cell imaging for antibiotic susceptibility testing
Johan Elf (Uppsala, Sweden)

Therapeutic approaches to combat hetero-resistance in Gram-negative pathogens
David Weiss (Atlanta, United States)

Co-organised with: ESMID Scientific Affairs Subcommittee

1-hour Symposium

Bacteriophage therapeutics for biofilm infections: hopes and hurdles

Bacteriophages for difficult-to-treat infections: a clinical perspective
Christian Van Delden (Geneva, Switzerland)

Strategies to improve phage therapy against chronic infections
Joana Azeredo (Braga, Portugal)

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

1-hour Symposium

Biofilms and *Clostridioides difficile* infection recurrence

Building of biofilm, a metabolic reprogramming
Bruno Dupuy (Paris, France)

Biofilm and *Clostridioides difficile* infection recurrences
Ines Moura (Leeds, United Kingdom)

Co-organised with: ESCMID Study Group for *Clostridioides difficile* (ESGCD)

1-hour Symposium

Tough nuts to crack: the challenges and future of VRE infection and treatment

Immunomodulatory approaches to treating VRE infection
Kimberly Kline (Geneva, Switzerland)

Combinatorial treatment strategies for VRE
Josè M. Miro (Barcelona, Spain)

1-hour Symposium

Neuroimmune-modulation in infections: from pathogenic mechanisms to novel adjunct therapies

Bacteria hijack the neuroimmune axis for bacterial invasion
TBA

Understanding inflammation through neuroscience
Peder Olofsson (Stockholm, Sweden)

1-hour Symposium

Vaccine preventable diseases in the immunocompromised host: new developments

Strategies to enhance vaccination uptake in immunocompromised patients
Ben Teh (Melbourne, Australia)

The role of monoclonal antibodies in preventing infection
Natasha Halassa (Nashville, United States)

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH)

1-hour Symposium

Top papers in immunocompromised infectious diseases

Top papers in SOT ID
Hans Hirsch (Basel, Switzerland)

Top papers in HSCT/primary immunodeficiency ID
Clarisse Machado (Sao Paulo, Brazil)

Preliminary Programme

1-hour Symposia | Meet-the-Expert

1-hour Symposium

Which randomised controlled trial do we need?

Missing evidence: clinical trials in life-threatening infectious diseases

Guy Thwaites (Ho Chi Minh City, Viet Nam)

Clinical trial design and data collection

Lauren Maxwell (Heidelberg, Germany)

Co-organised with: CMI Board of Editors, European Clinical Research Alliance on Infectious Diseases (ECRAID)

1-hour Symposium

Machine learning and generative AI in CM/ID practice

Generative AI – applications in CM/ID practice

Chang Ho Yoon (Oxford, United Kingdom)

The challenges and limitations of using AI in CM/ID

Catherine Jutzeler (Zurich, Switzerland)

Co-organised with: Trainee Association of ESCMID (TAE)
Steering Committee, ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD)

Meet-the-Expert
RSV control within reach
<i>Peter Openshaw</i> (London, United Kingdom)
TBA

Meet-the-Expert
Guidance for influenza treatment
<i>Barbara Rath</i> (Besancon, France)
<i>Giulia De Angelis</i> (Rome, Italy)
Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV)

Meet-the-Expert
Post-exposure prevention of STIs with antibiotics: pros and cons
<i>Deniz Gokengin</i> (Izmir, Turkey)
<i>Jean-Michel Molina</i> (Paris, France)
Co-organised with: Euroguidelines in Central and Eastern Europe (ECEE) Network Group

Meet-the-Expert
Using antimicrobial susceptibility testing of nontuberculous mycobacteria to improve clinical practice
<i>Jakko van Ingen</i> (Nijmegen, Netherlands)
<i>Claire Andrejak</i> (Amiens, France)
Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC)

Meet-the-Expert
How to use follow-up blood cultures in patients with Gram-negative bacteraemia
<i>Joshua Thaden</i> (Durham, United States)
<i>Mo Yin</i> (Singapore, Singapore)
Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES)

Meet-the-Expert
Treatment of infective endocarditis: back to the future
<i>Mia Marie Pries-Heje</i> (Copenhagen, Denmark)
<i>Eugene Athan</i> (Geelong, Australia)

Meet-the-Expert
How to use CRISPR-Cas to combat AMR
<i>Kelli Palmer</i> (United States)
<i>Peter Fineran</i> (Dunedin, New Zealand)

Meet-the-Expert
EUCAST Frequently Asked Questions in AST
<i>Erika Matuschek</i> (Växjö, Sweden)
<i>Rafael Canton</i> (Madrid, Spain)
Co-organised with: EUCAST Steering Committee

Meet-the-Expert
Controversies in diagnosis and treatment of difficult Gram-negative infections
<i>Veeraraghavan Balaji</i> (Vellore, India)
<i>Sasheela Ponnampalavanar</i> (Kuala Lumpur, Malaysia)

Meet-the-Expert
Those who are now named: identifying "difficult" bacteria
<i>Belen Rodriguez Sanchez</i> (Madrid, Spain)
<i>Alida Veloo</i> (Groningen, Netherlands)
Co-organised with: ESCMID Study Group for Anaerobic Infections (ESGAI)

Meet-the-Expert
Spitting image: using saliva as a diagnostic sample
<i>Rachel Byrne</i> (Liverpool, United Kingdom)
<i>Anne Wyllie</i> (New Haven, United States)
Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV)

Preliminary Programme

Meet-the-Expert

Meet-the-Expert

The role of local microbiology in a world of high throughput off-site labs

Robin Patel (Rochester, United States)

*Patrick Jeurissen
(Nijmegen, Netherlands)*

Meet-the-Expert

The sustainable microlab - how green can we become?

Jane Kilcoyne (Oranmore, Ireland)

TBA

Meet-the-Expert

The dish of the day: individualised antibiotic dosing in critically ill patients

Uwe Liebchen (Munich, Germany)

*Sonya Tang Girdwood
(Cincinnati, United States)*

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Critically Ill Patients (ESGCIP)

Meet-the-Expert

PK/PD modelling: from bench to bedside

Sebastian Wicha (Hamburg, Germany)

Angela Huttner (Geneva, Switzerland)

Meet-the-Expert

Diagnosing fungal infections in clinical practice

Katrien Lagrou (Leuven, Belgium)

Bart Rijnders (Rotterdam, Netherlands)

Co-organised with: ESCMID Fungal Infection Study Group (EFISG), Société belge infectiologie et de microbiologie clinique (SBIKM)

Meet-the-Expert

Emerging strategies for invasive fungal disease management

Carolina Garcia Vidal (Barcelona, Spain)

Anna Khanina (Melbourne, Australia)

Co-organised with: ESCMID Fungal Infection Study Group (EFISG)

Meet-the-Expert

Diagnosis and treatment of rare infections in migrants and travellers

*Watcharapong Piyaphanee
(Bangkok, Thailand)*

Adesola Yinka-Ogunleye (Abuja, Nigeria)

Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

Meet-the-Expert

Cardiovascular implant infections: current challenges

Barbara Hasse (Zurich, Switzerland)

Alexander Maas (Groningen, Netherlands)

Co-organised with: ESCMID Study Group for Implant-associated Infections (ESGIAI)

Meet-the-Expert

Improving implementation in infection prevention and control

Gabriel Birgand (Nantes, France)

Lauren Clack (Zurich, Switzerland)

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), Trainee Association of ESCMID (TAE) Steering Committee, EUCIC Steering Committee

Meet-the-Expert

Nosocomial infection in the adult patient with ECMO support

*Marta María Hernández
(Barcelona, Spain)*

Konstanty Szuldrzyński (Krakow, Poland)

Co-organised with: EuroELSO

Meet-the-Expert

When colonisers run amok: how to study carriage of bacteria

*Carmen Munoz-Almagro
(Barcelona, Spain)*

Adam Finn (Bristol, United Kingdom)

Meet-the-Expert

Children are not just small adults: interactive paediatric cases

Julie Toubiana (Paris, France)

*Sanjay Patel
(Winchester, United Kingdom)*

Co-organised with: European Society of Paediatric Infectious Diseases (ESPID)

Meet-the-Expert

When to say yes: selecting organ donors with known infections

Ann Wooley (Boston, United States)

Alessandra Mularoni (Palermo, Italy)

Meet-the-Expert

Using foresight for disease preparedness and response

Gerjon Ikink (Stockholm, Sweden)

Klaudia Palczak (Lisbon, Portugal)

Co-organised with: European Centre for Disease Prevention and Control (ECDC)

Preliminary Programme

Educational Sessions

Educational Session

Guide to HIV-associated opportunistic infections

Rare and difficult-to-treat HIV-associated opportunistic infections

Arjan Harxhi (Tirana, Albania)

Should we diagnose and treat opportunistic infections differently in HIV than in other immunocompromised patients?

Daria Podlekareva

(Copenhagen, Denmark)

Prophylaxis of opportunistic infections

Anton Pozniak (London, United Kingdom)

Are opportunistic infections still a problem in European countries in the ART era?

Cristiana Oprea (Bucharest, Romania)

Co-organised with: Euroguidelines in Central and Eastern Europe (ECEE) Network Group, Danish Infectious Disease Society

Educational Session

Exotic viral hepatitis: from changing epidemiology to appropriate case management

Rare but deadly - HSV Hepatitis during pregnancy

TBA

Diagnosis and prevention of vector-borne hepatitis

Önder Ergönül (Istanbul, Turkey)

Flaviviral hepatitis acquired in endemic destinations

Antonio Bandeira (Salvador, Brazil)

Viral hepatitis in returning travellers: beyond major hepatotropic viruses

Karine Lacombe (Paris, France)

Co-organised with: ESCMID Emerging Infections Task Force (EITaF) chair, ESCMID Study Group for Viral Hepatitis (ESGVH), GeoSentinel, FIGO (The International Federation of Gynecology and Obstetrics), Colombian Association of Infectious Diseases

Educational Session

How to deal with urinary tract infections in 2024: from guidelines to practice

The IDSA 2023 guidelines: new definitions and new approaches to 'uncomplicated' and 'complicated' UTI

Barbara Trautner (Houston, United States)

The European Urological Association's 2023 guideline: how to deal with prostatitis and other complicated UTIs

Florian Wagenlehner (Giessen, Germany)

Short course treatment of UTI: still works?

Kalpna Gupta (Boston, United States)

Antibiotic stewardship for UTI in primary care

Theo Verheij (Utrecht, Netherlands)

Co-organised with: ESCMID Guidelines Subcommittee

Educational Session

Management of lower respiratory tract infections

Cutting edge diagnostics in LRTI

Kev Dhaliwal (Edinburgh, United Kingdom)

Colonisation or infection in patient with underlying bronchiectasis

Eva Polverino (Barcelona, Spain)

Treatment and telemetric monitoring: towards a virtual ward at home

Annelies Verbon (Utrecht, Netherlands)

Health technology assessment of diagnostic strategies

Alec Morton (London, United Kingdom)

Co-organised with: Value-Dx

Educational Session

Rapid detection of antibiotic resistance – state-of-the-art

**Molecular-based AMR detection:
still the panacea?**

*Surbhi Malhotra-Kumar
(Antwerp, Belgium)*

**Non-molecular approaches for wide
implementation**

Jaroslav Hrabak (Prague, Czech Republic)

**How current rapid diagnostic tests can
support antibiotic stewardship?**

Evelina Tacconelli (Verona, Italy)

**Rapid diagnostic for AMR: what would I
need as a clinician in a perfect world?**

Florence Ader (Lyon, France)

Co-organised with: ESCMID Study Group for Antimicrobial
Resistance Surveillance (ESGARS)

Educational Session

EUCAST Educational Session

EUCAST Update

Christian Giske (Stockholm, Sweden)

**An update on antifungal susceptibility
testing and resistance screening**

*Maiken Cavling Arendrup
(Copenhagen, Denmark)*

Paediatric dosing

*Malte Kohns Vasconcelos
(Hamburg, Germany)*

Endocarditis breakpoints

Christoffer Lindemann (Bergen, Norway)

**Beta-lactamase/beta-lactamase
Inhibitors**

Shampa Das (Liverpool, United Kingdom)

Co-organised with: European Committee on Antimicrobial
Susceptibility Testing (EUCAST)

Educational Session

The use of metagenomics in diagnostics and surveillance

**Use of metagenomics to enhance
diagnosis of encephalitis**

Judy Breuer (London, United Kingdom)

**Utility of metagenomics to enhance the
management of severe respiratory
infections**

TBA

**Combining host response profiling
with metagenomics: is this the future of
infectious disease diagnostics?**

*Charles Chiu
(San Francisco, United States)*

**Routine implementation of metagenomics
in the clinic - what's next?**

Nicole Fischer (Hamburg, Germany)

Co-organised with: European Society for Clinical Virology
(ESCV)

Educational Session

Empowering young microbiologists: bioinformatic tools for routine workflows

**Why bioinformatics is the future of clinical
microbiology: impact of data-driven
approaches**

Torsten Seeman (Melbourne, Australia)

**Easy bioinformatics projects as a starting
point for bigger discoveries**

Oliver Schwengers (Giessen, Germany)

**Translating bioinformatics into clinical
utility**

Anita Schürch (Utrecht, Netherlands)

**Building capacity: Investing in a
bioinformatician or bioinformatic
software?**

Helena Seth-Smith (Zurich, Switzerland)

Co-organised with: ESCMID Study Group for Genomic and
Molecular Diagnostics (ESGMD), Trainee Association of
ESCMID (TAE) Steering Committee

Preliminary Programme

Educational Sessions

Educational Session

Practical implications of the EU *in vitro* diagnostic medical device regulation for clinical microbiology

The role of EQA/PT providers in post market surveillance according to EU IVDR
Christoph Buchta (Vienna, Austria)

How to interpretate IVDR for culture-based diagnostic methods
Peter Vermeersch (Leuven, Belgium)

Experience from production of in house IVDs according to IVDR
Andreas Resar (Umeå, Sweden)

Into the unknown: formulating society guidelines for interpreting and implementing IVDR in clinical microbiology laboratories
Helle Brander Eriksen (Copenhagen, Denmark)

Co-organised with: Nordic Society of Clinical Microbiology and Infectious Diseases (NSCMID), Biomed Alliance

Educational Session

The big cinema of treating infectious diseases: blockbusters and evergreens

The good, the bad and the ugly: the reality behind antibiotics with broad and narrow therapeutic index
Maya Hites (Brussels, Belgium)

Highlander, there can be only one: clinically relevant drug interactions with antimicrobials
Markus Zeitlinger (Vienna, Austria)

Mission impossible? Treatment of deep-seated infections and biofilms
Oana Ciofu (Copenhagen, Denmark)

From dusk till dawn – what is the real value of continuous antibiotic infusion at the ICU?
Isabel Spriet (Leuven, Belgium)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

Educational Session

The alfa and omega of antimicrobial stewardship: optimising antimicrobial therapy at hospital entry and discharge

Optimising antimicrobial therapy in the emergency room: the role of rapid diagnostics
Cihan Papan (Bonn, Germany)

ESCMID guidelines for antimicrobial stewardship at the emergency room
Teske Schoffelen (Nijmegen, Netherlands)

Careful goodbye at the door: antimicrobial stewardship interventions for antimicrobials on hospital discharge
Valerie Vaughn (Salt Lake City, United States)

How to deal with overuse at discharge in a resource limited setting
Florence Lieutier-Colas (Strasbourg, France)

Co-organised with: ESCMID Study Group for Antimicrobial stewardship (ESGAP)

Educational Session

Multidisciplinary teams for selecting antimicrobial therapy for bone and joint infections: the key for success

Selection of an appropriate treatment for bone and joint infections in real patients: a puzzle of controversies
Joan Gómez (Barcelona, Spain)

What do we need from a microbiologist? The MIC or the MBIC: new information about PK/PD in biofilms
Claus Moser (Copenhagen, Denmark)

The role of a clinical pharmacist in antibiotic treatment individualisation of special populations
Isabel Spriet (Leuven, Belgium)

Long-term suppressive antimicrobial treatments for BJI: the risk of toxicity and development of resistance
Parham Sendi (Bern, Switzerland)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

Educational Session

Treating CNS infections using modelling approaches: a translational point of view

Factors determining drug selection for CNS infections

Christina König (Hamburg, Germany)

Physiologically-based modelling in the study of antibiotic distribution in the CNS

Alexia Chauzy (Poitiers, France)

Understanding the blood brain barrier, the blood-CSF barrier and beyond

Bettina Pfausler (Innsbruck, Austria)

PK/PD of antibiotics and antimicrobial resistance in CNS infections: a clinical point of view

Gauri Rao (Chapel Hill, United States)

Co-organiser: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

Educational Session

The changing faces of fungi

***Candida auris*: a growing threat**

TBA

***Blastomyces*: beyond an outbreak**

Anastasia Litvintseva

(Atlanta, United States)

Update on *Scedosporium* & *Lomentospora*

Fanny Lanternier (Paris, France)

Talk to me about Talaromycosis

Sirida Youngchim (Chang Mai, Thailand)

Educational Session

Rising to the challenge: new approaches to combat fungal infections and improve patient outcomes

Fungal disease: the view of the patients

Rob Purdie (Bakersfield, United States)

Access to diagnosis of fungal disease: from the point of care to the diagnostic laboratory hub

Narda Medina (Guatemala, Guatemala)

Challenges in the treatment of fungal infections in LMICs

Nelesh Govender

(Johannesburg, South Africa)

Management of implant-associated fungal infections

Georgia Vrioni (Athens, Greece)

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Implant-associated Infections (ESGII)

Educational Session

Challenging infectious diseases among immigrant immunosuppressed patients

Histoplasmosis

Ana Belen Arauz (Panama, Panama)

Chagas disease

TBA

Leishmaniasis

Johan van Griensven (Antwerp, Belgium)

Paracoccidioidomycosis

Rosane Hahn (Cuiaba, Brazil)

Educational Session

III travellers from around the globe: case-based approach

Destination: Latin America

Carlos Seas (Lima, Peru)

Destination: Africa

Jose Muñoz (Barcelona, Spain)

Destination: Asia

Andreas Neumayr (Basel, Switzerland)

Destination: Boreal regions

TBA

Co-organised with: Association of Medical Microbiology and Infectious Disease Canada (AMMI Canada)

Preliminary Programme

Educational Sessions

Educational Session

Infection prevention and control (IPC) around the world - learning from each other

Challenges and practices for IPC: diverse populations, environment and pathogens
Rajalakshmi Ananthanarayanan
(Trivandrum, India)

Preventing surgical site infections
Peter Nthumba (Kijabe, Kenya)

The role of the microbiology lab in IPC
Camilla Rodrigues (Mumbai, India)

Surveillance of multidrug-resistant microorganisms
Anucha Apisarnthanarak
(Bangkok, Thailand)

Co-organised with: Clinical Infectious Diseases Society of India

Educational Session

Environmental stewardship: cleaning the occupied bed space

How to clean the occupied patient room
Stepahine Dancer
(Glasgow, United Kingdom)

Are probiotic disinfectants effective in hospitals?
Elisabetta Caselli (Ferrara, Italy)

Continuous UV-C light in the clinical environment
Curtis Donskey (Cleveland, United States)

How to conduct real-life trials assessing hospital cleaning
Rasmus Leistner (Berlin, Germany)

Educational Session

Primer on infection prevention and control of multidrug-resistant Gram-negative bacilli

When to add an environmental contamination investigation: outbreaks and endemic situations
Lorena Lopes-Cerero (Sevilla, Spain)

Treatment, prophylaxis and decolonisation of MDRGN carriers
Elena Carrara (Verona, Italy)

Tailoring infection prevention strategies to cultural realities
Michael Borg (Msida, Malta)

New infection prevention and control strategies
Nico Mutters (Bonn, Germany)

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee

Educational Session

Clostridioides difficile infection (CDI): managing complex cases

Severe case: to operate or not?
TBA

Multiple recurrent CDI: where to you go when FMT is not an option?
Gianluca Ianiro (Rome, Italy)

Live biotherapeutic products for recurrent CDI: what's new?
Elena Reigadas (Madrid, Spain)

Friday of a bank holiday: CDI outbreak, now what?
Karen Burns (Dublin, Ireland)

Co-organised with: ESCMID Study Group for *Clostridioides difficile* (ESGCD), ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI)

Educational Session

Outbreaks in healthcare settings: practical guidance and case scenarios

Influx of infections: case scenario and simulation exercise

Sotirios Tsiodras (Athens, Greece)

MDRO outbreak in hospitals: case scenario and simulation exercise

Bojana Beovic (Ljubljana, Slovenia)

Managing an outbreak of *Candida auris*

Tanu Singhal (Maharashtra, India)

Prevention of endoscopy-related outbreaks

Lawrence Hookey (Kingston, Canada)

Co-organised with: EUCIC Steering Committee

Educational Session

Staphylococcus aureus: from bench to bedside

New insights into *S. aureus* biology

Andreas Peschel (Tübingen, Germany)

Unravelling *S. aureus* intracellular lifestyles by phenotypic profiling

Ana Eulalio (London, United Kingdom)

Interactions of *S. aureus* with the immune system

Nina van Sorge (Amsterdam, Netherlands)

Clinical trials of new and non-conventional approaches for *S. aureus* infections

Steven Tong (Surrey Hills, Australia)

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Implant-associated Infections (ESGII), ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

Educational Session

Diagnostic and management dilemmas in immunocompromised hosts: you be the judge

Invasive fungal infection prior to HSCT

Johan Maertens (Leuven, Belgium)

MDRO *Burkholderia* spp and lung transplantation

Saima Aslam (San Diego, United States)

Resistant CMV infection in a patient with immunodeficiency

Elisa Cordero (Seville, Spain)

Infections in decompensated cirrhosis

Salvatore Piano (Padua, Italy)

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), European Association for the study of the liver (EASL)

Educational Session

Infections and inborn errors of immunity. When to think and how to act

Genetic predisposition for infectious diseases

TBA

When should an inborn error of immunity be suspected in an adult?

Siobahn Burns (London, United Kingdom)

Immunomodulatory therapy: when antibiotics are not enough

Steven Holland (Bethesda, United States)

Antimicrobial prophylaxis in patients with Inborn Errors of Immunity

Olaf Neth (Seville, Spain)

Co-organised with: European Society of Immunodeficiencies

Preliminary Programme

Educational Sessions | Open Forum

Educational Session

Clinical practice guidelines on ID: present and future

Behind the curtain: how guidelines are made

Blin Nagavci (Gjakove, Kosovo)

IncOrPorating Ethics iN Clinical Guidelines: The ESCMID OPENING project

Elda Righi (Verona, Italy)

AI for Guideline development: opportunities and pitfalls

TBA

The future of guidelines: what's next

Jose Ramon Pano Pardo (Zaragoza, Spain)

Co-organised with: ESCMID Ethics Advisory Committee (EEAC), ESCMID Publication Subcommittee, ESCMID Guidelines Subcommittee

Educational Session

AI tools transforming scientific research and communication

Using generative AI in scientific research: opportunities and risks

TBA

AI shaping the future of scientific writing and publishing

Ursula Hofer (London, United Kingdom)

(Mis)information fuelled by AI tools

TBA

AI tools: does AI-generated text challenge the core values of research?

David B. Resnik (Durham, United States)

Co-organised with: CMI Board of Editors

Open Forum

Going green: infection and sustainability

Reduction of energy use in the lab

Rolf Slaats (Twente, Netherlands)

Sustainability and IPC: friend or foe?

Andreas Voss (Groningen, Netherlands)

Do we really need all these gloves?

Sarah Tschudin-Sutter

(Basel, Switzerland)

Co-organised with: ESCMID Scientific Affairs Subcommittee, International Society of Antimicrobial Chemotherapy (ISAC)

Open Forum

Research integrity in clinical microbiology and infectious diseases

Eliminating "helicopter research" in CM/ID

Nada Fadul (Omaha, United States)

Women's representation in clinical trials: between participants and PIs

Dafna Yahav (Ramat-Gan, Israel)

Women's authorship and editorship in CM/ID journals

Katharina Last (Bonn, Germany)

Informed consent: the balance between patient autonomy and broad representation of populations in trials

Muge Cevik (Edinburgh, United Kingdom)

Co-organised with: CMI Board of Editors, ESCMID Ethics Advisory Committee (EEAC)

Open Forum

Building capacity and addressing inequalities in AMR surveillance

Strengthening laboratory capacity in resource-limited settings for reliable AST results

Biljana Kakaraskoska Boceska

(Antwerp, Belgium)

Ten years of CAESAR EQA: achievements, challenges and unmet needs

Onur Karatuna (Växjö, Sweden)

How to foster equitable partnership and mentorship models in international collaborations in AMR

Muneera Rasheed (Karachi, Pakistan)

Ensuring patient representation and voice in AMR focused interventions

Oluchi Mbamalu

(Cape Town, South Africa)

Co-organised with: CAESAR network, Dutch Society for Medical Microbiology (NVMM)

Open Forum

Professional skills that enhance performance in CM/ID

Resilience and work engagement

Juanjo Beunza (Madrid, Spain)

Communication skills of physicians and patients' satisfaction

TBA

Communicating antibiotic prescribing to patients

TBA

Co-organised with: Trainee Association of ESCMID (TAE) Steering Committee

Preliminary Programme

Open Forum | Year in Symposia

Open Forum

Publishing in CM/ID: continuing challenges

Caveat author: (semi-) predatory journals in CM/ID

Leonard Leibovici (Petah-Tiqva, Israel)

Selecting the best journal: looking beyond impact factor

Cesar Arias (Houston, United States)

Pathways to overcome intersectoral disadvantage in scientific publication

Esayas Kebede (Jimma, Ethiopia)

The role of qualitative research in infectious diseases

Dena van den Bergh

(Cape Town, South Africa)

Co-organised with: British Society for Antimicrobial Chemotherapy (BSAC), ESCMID Parity Commission

Open Forum

Research barriers and enablers in CM/ID

The European Data Health Space

Marieke Meijer (Brussels, Belgium)

Inter-continental collaborations: the Brazilian Pasteur experience

Marcio Rodrigues (Brasilia, Brazil)

Overcoming language barriers in research: a double jeopardy

Mehboob Mehboob (Swabi, Pakistan)

Barriers in training for quality research

Ibuchukwu Orabueze (Enugu, Nigeria)

Co-organised with: Biomed Alliance, ESCMID Ethics Advisory Committee (EEAC), ESCMID Parity Commission

Open Forum

AMS: a team sport involving all health professionals

The contribution of nurses to Antimicrobial Stewardship

Maria Clara Padoveze (Sao Paulo, Brazil)

Embedding antimicrobial stewardship in integrated community case management programmes

Sorawat Sangkaew (Songkhla, Thailand)

Rational microbiological diagnostics for AMS

Brita Skodvin (Bergen, Norway)

Co-organised with: ESCMID Study Group for Antimicrobial stewardship (ESGAP)

1-hour Symposium

Year in infectious diseases

Oana Sandulescu (Bucharest, Romania)

Nur Benzonana (Istanbul, Turkey)

1-hour Symposium

Year in public health

Alexandra Mailles (Paris, France)

Ziad Memish (Riyadh, Saudi Arabia)

1-hour Symposium

Year in clinical microbiology

Patricia Munoz (Madrid, Spain)

*Arjana Tambic Andrasevic
(Zagreb, Croatia)*

1-hour Symposium

Year in infection control

*Stephan Juergen Harbarth
(Geneva, Switzerland)*

Elisabeth Presterl (Vienna, Austria)